Navigation Links
R. Lindholm Named to Crux Biomedical Board
Date:3/14/2011

MENLO PARK, Calif., March 14, 2011 /PRNewswire/ -- Crux Biomedical, developer of an advanced implantable vena cava filter (IVCF) to prevent pulmonary embolisms, announced the appointment of Randy Lindholm to its Board of Directors. Mr. Lindholm is a widely respected advisor to the medical device field. He was previously Chairman and CEO of Vidamed,  a maker of minimally invasive medical devices to treat benign prostate hyperplasia until it was acquired by Medtronic in 2002.  Prior to Vidamed, Randy held senior positions at Nellcor Puritan Bennett and GE Medical Systems. " I am excited to join Crux Biomedical. They are well positioned to take advantage of the current interest in a better performing retrievable IVC filter," stated Mr. Lindholm. He currently serves as director of publically held Omnicell (MLCL), Barrx Medical, Tibion Bionic Technologies, Estech and Novasys Medical.

"We are very pleased to have Randy's operating experience at Crux," states Mel Schatz, CEO of Crux Biomedical. He continued, "Randy has assisted numerous firms in securing venture backed funding."  Crux Biomedical is currently enrolling patients in its pivotal IDE study in the United States and several sites internationally. It expects to complete the U.S. study in 2011 and launch internationally  later this year.

Crux Biomedical was founded in 2004 by Thomas Fogarty, M.D., to target the development of an advanced implantable inferior vena cava filter (IVCF) to prevent the occurrence of potentially fatal pulmonary embolisms. Although routinely used in the United States, currently cleared IVC filters are associated with a variety of complications. "We recognized current IVC filters did not meet the needs of clinicians and designed a filter that provided better retrievability," stated Tom Fogarty, M.D.

Each year in the United States approximately 600,000 patients develop a PE and an estimated 200,000 deaths occur. Pulmonary embolisms are recognized as the most frequent cause of death among hospitalized patients.

Crux Biomedical is located in Menlo Park, California and is funded by Alloy Ventures and Emergent Medical Partners.


'/>"/>
SOURCE Crux Biomedical
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Ferring Pharmaceuticals, Inc. Congratulates R&B and Pop Icon Gloria Gaynor, Named Woman of the Year by Arthritis Foundation
2. Michael Petras, Former CEO of GE Lighting, Named CEO of Cleveland-Based Specialty Medical Supplies Leader
3. Living Medical eTextbook iPhone App from Projects In Knowledge® Named to Top 20 List of Free Medical Apps
4. Dawn Phillips Named as Vice President, Business Development for Catastrophic & Home Health Services
5. Pfizer Chief Medical Officer Freda Lewis-Hall Named 2011 Woman of the Year by The Healthcare Businesswomens Association
6. Dynatronics Named Contract Supplier to Amerinets 50,000 Members
7. R&J Public Relations Named Agency of Record for Aerocrine, Inc.
8. Stryker Corporation Named One of FORTUNE Magazines 100 Best Companies to Work For
9. Kevin Banion Named CEO of Progressive Medical, Inc.
10. Webmedx Named Best in KLAS and Ranked #1 Transcription Services Vendor for Second Year in a Row
11. Elektas MOSAIQ Oncology Information System Named Category Leader in 2010 Top 20 Best in KLAS Awards Report
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/23/2017)... 23, 2017 Persistence Market ... global market for intraoperative imaging, excerpts from which ... US$ 513.9 million. According to the report, the ... the grounds of increasing adoption of minimally-invasive surgeries ... diagnostic imaging for neurosurgeries. The world,s leading medical ...
(Date:2/23/2017)... -- Research and Markets has announced the addition of ... Industry Forecast to 2025" report to their offering. ... The Global Cardiac Prosthetic ... 9.2% over the next decade to reach approximately $8.9 billion by ... forecasts for all the given segments on global as well as ...
(Date:2/23/2017)... 2017 MabVax Therapeutics Holdings, Inc ... company, announces that it has received notice from ... the initiation a Phase I clinical trial with ... MVT-1075 ( 177 Lu-CHX-A?-DTPA-HuMab5B1) is the Company,s novel ... initiate the phase I clinical trial in patients ...
Breaking Medicine Technology:
(Date:2/23/2017)... ... February 23, 2017 , ... HealthPostures, the desk for standing designer ... stand solutions representative to the Minneapolis Home and Garden Show which is being held ... is garnering national attention is the Minneapolis Convention Center. , From its broad ...
(Date:2/22/2017)... ... February 22, 2017 , ... When it came time to ... in Georgia, PENETRON Specialty Products (PSP) provided the solution. January’s grand opening presented ... $51 million to purchase and renovate the 185,000 square-foot office complex, which was ...
(Date:2/22/2017)... ... February 22, 2017 , ... Stem cell therapy ... The technology is so cutting edge, in fact, the U.S. Food and Drug ... procedures. However, successful patient outcomes in certain clinical stem cell procedures have shown ...
(Date:2/22/2017)... , ... February 22, 2017 , ... ... certification exam and eligibility requirements effective with the April 2017 testing period. NACCM, ... , “The Care Manager Certified (CMC) exam is periodically re-calibrated to ensure ...
(Date:2/22/2017)... ... February 22, 2017 , ... ... analytics to accurately understand each Medicare Advantage member’s risk, identify any gaps-in-coding, ... This new solution helps transform the HCC Risk Adjustment process from a ...
Breaking Medicine News(10 mins):